Diabetes was Accendra Health’s largest product and service line in fiscal 2025, bringing in $783.37M of $2.76B (28%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Diabetes | $777.48M | $783.37M |
| Sleep Therapy | $702.95M | $740.05M |
| Home Respiratory Therapy | $435.95M | $433.05M |
| Other | $268.27M | $288.19M |
| Ostomy | $195.92M | $212.84M |
| Wound Care | $192.41M | $188.51M |
| Urology | $107.12M | $116.02M |
| Total | $2.68B | $2.76B |
Accendra Health brought in $2.76B from its seven product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 3.1% from $2.68B in fiscal 2024. Diabetes was the largest at $783.37M (28.4%), ahead of Sleep Therapy at $740.05M (26.8%) and Home Respiratory Therapy at $433.05M (15.7%). The other four lines brought in $805.56M combined.
Compared with fiscal 2024, Ostomy grew fastest, up 8.6% to $212.84M, while Wound Care fell the most, down 2.0% to $188.51M.
Commercial Payors was Accendra Health’s largest revenue line in fiscal 2025, bringing in $2.23B of $2.82B (79%).
| Customer | FY 2024 | FY 2025 |
|---|---|---|
| Commercial Payors | $2.18B | $2.23B |
| Largest Commercial Payors | — | $553.00M |
| Medicare | $461.97M | — |
| Medicaid | $40.18M | $38.46M |
| Total | $2.68B | $2.82B |
Accendra Health brought in $2.82B from its three revenue lines in fiscal 2025, the year ended December 31, 2025. Accendra Health regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $2.68B. Commercial Payors was the largest at $2.23B (79.0%), ahead of Largest Commercial Payors at $553.00M (19.6%) and Medicaid at $38.46M (1.4%).
Accendra Health began breaking out Largest Commercial Payors in fiscal 2025, when it brought in $553.00M. Accendra Health stopped reporting Medicare as a separate revenue line after fiscal 2024, when it brought in $461.97M.
Guarantor Subsidiaries was Accendra Health’s largest revenue line in fiscal 2014, bringing in $8.91B of $9.54B (93%).
| Legal Entity | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 |
|---|---|---|---|---|---|---|
| Guarantor Subsidiaries | $8.63B | $8.73B | $8.69B | $8.91B | ||
| Non-Guarantor Subsidiaries | $126.00K | $165.19M | $435.04M | $626.04M | ||
| Eliminations | — | -$28.35M | -$50.63M | — | ||
| Total | $8.63B | $8.87B | $9.07B | $9.54B |
Accendra Health brought in $9.54B from its two revenue lines in fiscal 2014, the year ended December 31, 2014. Accendra Health regrouped these revenue lines after fiscal 2013, so the total does not compare directly with that year's $9.07B. Guarantor Subsidiaries was the largest at $8.91B (93.4%), ahead of Non-Guarantor Subsidiaries at $626.04M (6.6%).
Compared with fiscal 2013, Non-Guarantor Subsidiaries grew 43.9% to $626.04M and Guarantor Subsidiaries grew 2.6% to $8.91B. From fiscal 2011 to 2014, combined revenue from these revenue lines grew from $8.63B to $9.54B, a compound annual growth rate of 3.4%. Guarantor Subsidiaries' share of the total fell from 100.0% to 93.4%.
Accendra Health (ACH) reports its revenue by product and service, by customer and by legal entity. In fiscal 2025, Diabetes was its largest product and service line, bringing in $783.37M (28.4% of the total), followed by Sleep Therapy at $740.05M (26.8%).
Diabetes was Accendra Health's largest product and service line in fiscal 2025, bringing in $783.37M, or 28.4% of the $2.76B total across its seven product and service lines.
Commercial Payors was Accendra Health's largest revenue line in fiscal 2025, bringing in $2.23B, or 79.0% of the $2.82B total across its three revenue lines.
Among Accendra Health's product and service lines that make up at least 2% of revenue, Ostomy grew fastest in fiscal 2025, up 8.6% from $195.92M to $212.84M.
Every figure comes from Accendra Health's annual financial filings, as reported. Each line keeps the name Accendra Health gives it, and years follow its fiscal calendar.
Accendra Health's revenue by product and service goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.